Latest Articlesddd

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

January 11, 2017 0

Amgen (AMGN) The Journal of the American Medical Association (JAMA) published findings from three Phase 3 …

Takeda Acquires Ariad for $5.2 Billion

January 9, 2017 0

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be …

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

January 6, 2017 0

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center …

Some More Important News that Precedes the Upcoming Prohost Letter

January 5, 2017 0

GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded …

A Few News Before Posting the New Year Prohost Letter

January 3, 2017 0

Hi and Happy New Year 2017 In a couple of days, you will receive the NEW …

The FDA Manufacturing Issues. Why Portola Rallied but is Still Way Undervalued

December 26, 2016 0

MANUFACTURING ISSUES?!  Why PORTOLA Stock Rallied? On Aug. 17, 2016, we learned that the FDA sent …

Misunderstanding the Bipartisan Senate Report on Drug Prices. See Also: Incyte Signs a Promising Collaborative Agreement with Merus N.V.

December 22, 2016 0

Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors …

IONIS: Near Reaching the Hall of Fame

December 21, 2016 0

Ionis Pharmaceuticals (IONS) has further good news with a new revelation from Akcea Therapeutics, a wholly-owned …

Prohost Letter #403 Part 2

December 16, 2016 0

Prohost Letter #403 Part 2 Continued From Wednesday Instead of continuing yesterday article about Agenus, we …

Prohost Letter #403 Part 1

December 14, 2016 0

ProhostLetter #403 Part 1 On December 8, 2016 under News & Comments Prohost commented on President …

Ophthotech Bad News Adds to Regeneron Good News

December 12, 2016 0

Today we have good news and bad news. The good news is coming from Regeneron (REGN)through two …

Prohost Take on What’s Going on in the Drug Sector

December 8, 2016 0

President Elect Trump was quoted in a Time person of the year as saying “I am …

Bellicum Is Outperforming and So Should Be Its Stock

December 5, 2016 0

Bellicum Pharmaceuticals (BLCM) announced results from the BP-004 multicenter clinical trial for children with Primary Immune …

Prohost Letter #402

November 30, 2016 0

Prohost Letter #402 Antisense Proof of Concept and Feasibility EYE ON INVIVA (INVA) Sales of The …

It Is All About Array Biopharma

November 22, 2016 0

Prohost Biotech On   ARRAY PHARMACEUTICALS Under the title “Halozyme has Good News and Array Too”, we …

Prohost Letter #401

November 16, 2016 0

Prohost Letter #401 SYNOPSIS PART 1 In this Letter CONTENTS Duchenne Muscular Dystrophy (DMD) FDA Compassionate …

Adaptimmune: The FDA Removed the Temporary Ban on the Trial with NY-ESOS PEAR T-Cell Therapy for Mixoid Round Cell Liposarcoma

November 14, 2016 0

The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold it put on …

PTC Therapeutics Stock Price Doubles. When the Data Are Not Good for Forecasting.

November 11, 2016 0

The media failure to forecast the results of the Presidential election has become the talk of …

Ionis Drug Spinraza Conquers Spinal Muscular Atrophy with Statistically Significant Results

November 8, 2016 0

Biogen (BIIB) and Ionis (IONS) announced that Spinraza (nusinersen), an antisense drug designed and developed by …

Cempra Stock has Been Cremated. Will Today’s Good News Resurrect It?

November 7, 2016 0

The nature the Presidential Election this time is weighing on investors’ chests and minds and mood …